Search

Displaying results 5671 - 5680 of 9888 in total
  1. Drug

    NM3086

    go.drugbank.com/drugs/DB17719
    Experimental

    NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.[L46193]

  2. Drug

    OMS906

    go.drugbank.com/drugs/DB17722
    Investigational

    OMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.

  3. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    Rusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera. … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.

  4. Drug

    CSL-689

    go.drugbank.com/drugs/DB17726
    Investigational

    CSL689 is a recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).

  5. Drug

    MBP-091

    go.drugbank.com/drugs/DB17741
    Experimental

    MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).[L46212]

  6. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    Arexvy (respiratory syncytial virus vaccine, adjuvanted) is an adjuvanted vaccine developed by GlaxoSmithKline Biologicals. It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusi...

    Synonyms: RSVPreF3 OA, RSVPreF3 OA vaccine
  7. Drug

    AVP-21D9

    go.drugbank.com/drugs/DB17798
    Investigational

    AVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.[A259522]

  8. Drug

    BHV-5000

    go.drugbank.com/drugs/DB17817
    Experimental

    BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]

    Synonyms: (S)-1-(L-valyl)-N_((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide fumarate
  9. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56058,A275435] Navepegritide is a prodrug of active C-type natriuretic peptide (CNP) consisting of a CNP moiety transiently conjugated to two methoxy polyethylene glycol (mPEG) moieties via a proprietary … Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits

  10. Drug

    SIG-001

    go.drugbank.com/drugs/DB17826
    Investigational

    SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer